Side-by-side comparison of AI visibility scores, market position, and capabilities
British consumer health company with £14B revenue; Lysol, Mucinex, Nurofen, and Durex brands managing Mead Johnson infant formula litigation while competing with P&G and J&J.
Reckitt is a British multinational consumer health and hygiene company producing market-leading brands including Nurofen (ibuprofen), Strepsils, Dettol, Lysol, Durex, Mucinex, Enfamil infant formula, and Woolite — competing across OTC health, hygiene and home, and nutrition categories. Listed on the London Stock Exchange (LSE: RKT) and headquartered in Slough, England, Reckitt generates approximately £14 billion ($17 billion) in annual revenue. The company has undergone significant portfolio reshaping, divesting its Infant Formula & Child Nutrition (IFCN) business in some markets and selling Mead Johnson Nutrition operations.\n\nReckitt's business is organized into two segments: Health (Nurofen, Strepsils, Gaviscon, Mucinex, DayQuil/NyQuil in North America) and Hygiene and Home (Lysol/Dettol disinfectants, Finish dishwasher tablets, Vanish stain remover, Air Wick). The Health segment benefits from strong brand equity in OTC medications that command premium pricing. The Hygiene segment's Lysol brand benefited significantly from COVID-19 disinfectant demand and has sustained elevated brand awareness post-pandemic.\n\nIn 2025, Reckitt faces ongoing challenges from its $2.4 billion acquisition of Mead Johnson (Enfamil) — the company has faced significant litigation related to NEC (necrotizing enterocolitis) lawsuits claiming preterm infant formula contributed to infant deaths, resulting in large court judgments against Reckitt in 2024. The company is managing these legal liabilities while continuing to run its core consumer health and hygiene portfolio. Reckitt competes with Procter & Gamble, Johnson & Johnson, and Haleon for OTC health and hygiene market share. The 2025 strategy focuses on its Power Brands in health and hygiene, cost efficiency, and resolving the Mead Johnson litigation exposure.
Nation's largest homebuilder; 89,690 homes FY2024; $36.8B revenue; Express Homes entry-level focus; Forestar vertical land integration; rate buydown strategy sustains demand vs 6%+ mortgages.
D.R. Horton is the nation's largest homebuilder by volume, founded in 1978 by Donald Ray Horton in Fort Worth, Texas and now headquartered in Arlington, Texas, trading on NYSE (DHI). The company delivered approximately 89,690 homes in fiscal year 2024 (ending September 30) and generated $36.8 billion in revenues under CEO Paul Romanowski, who succeeded longtime CEO David Auld in 2024. D.R. Horton operates across 118 markets in 33 states, targeting the broadest range of price points in the industry from entry-level starter homes under the Express Homes brand through core D.R. Horton family homes to luxury properties under Emerald Homes and Freedom Homes age-restricted communities. The company's scale and geographic diversification provide resilience against regional housing market downturns and allow efficient land acquisition across America's fastest-growing metropolitan markets.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.